Loading...
•
Dec 31, 2024
Xeris Biopharma Q4 2024 Earnings Report
Xeris Biopharma reported record Q4 2024 revenue, achieving strong growth and positive cash flow while maintaining a disciplined financial strategy.
Key Takeaways
Xeris Biopharma reported a record Q4 2024 with total revenue of $60.10 million, reflecting a 35.4% year-over-year increase. Net loss improved significantly to $5.11 million from $13.39 million in Q4 2023. The company generated positive cash flow of $2 million and posted an Adjusted EBITDA of $8.3 million. Strong growth in Recorlev, which saw a 131% YoY increase in revenue, contributed significantly to the performance. The company ended the quarter with $71.62 million in cash, maintaining a strong financial position.
Q4 2024 revenue reached $60.10 million, a 35.4% YoY increase.
Net loss narrowed to $5.11 million from $13.39 million in Q4 2023.
Adjusted EBITDA improved to $8.3 million in Q4 2024.
Cash and cash equivalents stood at $71.62 million at quarter-end.
Revenue by Segment
Forward Guidance
Xeris Biopharma expects continued revenue growth in 2025, with total revenue projected between $255 million and $275 million, representing over 30% growth at the mid-point. Adjusted EBITDA is expected to remain positive.
Positive Outlook
- 2025 revenue projected to grow over 30% at the mid-point.
- Continued strong growth expected in Recorlev and Gvoke sales.
- Company maintains a disciplined financial strategy with positive EBITDA.
- Pipeline advancements, including XP-8121 for hypothyroidism, progressing.
- Strong liquidity position with over $71M in cash to support future growth.
Challenges Ahead
- Keveyis revenue declined by 21% in Q4 2024 due to lower product shipments.
- Ongoing investments in commercialization and R&D could impact short-term profitability.
- Competition in the biopharma space remains a risk to revenue growth.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...